Initial rivaroxaban dosing in patients with atrial fibrillation

BACKGROUND: Rivaroxaban is a non‐vitamin K oral anticoagulant and has been approved for prevention of stroke and systemic embolism in patients with non‐valvular atrial fibrillation (AF). Current labeling recommends 20 mg once a day (q.d.) as a standard dose and a reduced dose of 15 mg q.d. in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Ablefoni, Kaja, Buchholz, Alexander, Ueberham, Laura, Hilbert, Sebastian, Dagres, Nikolaos, Husser, Daniela, Hindricks, Gerhard, Bollmann, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2019
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788464/
https://www.ncbi.nlm.nih.gov/pubmed/31317562
http://dx.doi.org/10.1002/clc.23235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788464/
https://www.ncbi.nlm.nih.gov/pubmed/31317562
http://dx.doi.org/10.1002/clc.23235

Ejemplares similares